참고문헌
- AleAhmad S, Casey G, Sweeney P, et al (2009). Prostate stem cell antigen DNA vaccination breaks tolerance to selfantigen and inhibits prostate cancer growth. Mol Ther, 17, 1101-8. https://doi.org/10.1038/mt.2009.66
- Ahn SH (2004). Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg, 139, 27-30, discussion 1. https://doi.org/10.1001/archsurg.139.1.27
- Benson JR, Jatoi I, Keisch M, et al. (2009). Early breast cancer. Lancet, 373, 1463-79. https://doi.org/10.1016/S0140-6736(09)60316-0
- Berndt SI, Potter JD, Hazra A, et al. (2008). Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet, 17, 2665-72. https://doi.org/10.1093/hmg/ddn166
- Buck MB, Fritz P, Dippon J, et al. (2004). Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10, 491-8. https://doi.org/10.1158/1078-0432.CCR-0320-03
- Chen JQ, Brown TR, Russo J (2009). Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta, 1793, 1128-43. https://doi.org/10.1016/j.bbamcr.2009.03.009
- Chu LW, Meyer TE, Li Q, et al. (2010). Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev, 19, 1848- 54. https://doi.org/10.1158/1055-9965.EPI-10-0101
- Cianfrocca M, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13. https://doi.org/10.3322/caac.20029
- Coffey DS (2001). Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology, 57, 31-8. https://doi.org/10.1016/S0090-4295(00)00938-9
- Czajka-Oraniec I, Simpson ER (2010). Aromatase research and its clinical significance. Endokrynol Pol, 61, 126-34.
- Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Fletcher O, Johnson N, Gibson L, et al. (2008). Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 702-5. https://doi.org/10.1158/1055-9965.EPI-07-2564
- Frasor J, Danes JM, Komm B, et al. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 144, 4562-74. https://doi.org/10.1210/en.2003-0567
- Garcia-Closas M, Chanock S (2008). Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res, 14, 8000-9. https://doi.org/10.1158/1078-0432.CCR-08-0975
- Gluz O, Liedtke C, Gottschalk N, et al. (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27. https://doi.org/10.1093/annonc/mdp492
- Habel LA, Capra AM, Oestreicher N, et al. (2007). Mammographic density in a multiethnic cohort. Menopause, 14, 891-9. https://doi.org/10.1097/gme.0b013e318032569c
- Han JS, Cao D, Molberg KH, et al. (2011). Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triplenegative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triplenegative breast carcinomas. Am J Clin Pathol, 135, 230-7. https://doi.org/10.1309/AJCP9DV3EVZUATFV
- Imyanitov EN (2009). Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet, 125, 239-46. https://doi.org/10.1007/s00439-009-0636-7
- Jung KW, Park S, Kong HJ, et al. (2011). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat, 43, 1-11. https://doi.org/10.4143/crt.2011.43.1.1
- Kim BK, Lee JW, Park PJ, et al. (2009). The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res, 11, R22. https://doi.org/10.1186/bcr2247
- Li J, Humphreys K, Heikkinen T, et al. (2010). A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat.
- Lopez-Otin C, Diamandis EP (1998). Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev, 19, 365-96. https://doi.org/10.1210/er.19.4.365
- Matera L (2010). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41. https://doi.org/10.1016/j.ctrv.2009.11.002
- Matsuo K, Tajima K, Suzuki T, et al. (2009). Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer, 125, 1961-4. https://doi.org/10.1002/ijc.24519
- Offit K, Robson ME (2010). New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol, 28, 4665-6. https://doi.org/10.1200/JCO.2010.31.2926
- Onay VU, Briollais L, Knight JA, et al. (2006). SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 6, 114. https://doi.org/10.1186/1471-2407-6-114
- Orlando L, Schiavone P, Fedele P, et al. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev, 36 Suppl 3, S67-71. https://doi.org/10.1016/S0305-7372(10)70023-2
- Ozet A, Yavuz AA, Komurcu S, et al. (2000). Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol, 30, 188-90. https://doi.org/10.1093/jjco/hyd050
- Raff AB, Gray A, Kast WM (2009). Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett, 277, 126-32. https://doi.org/10.1016/j.canlet.2008.08.034
- Reiter RE, Gu Z, Watabe T, et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A, 95, 1735-40. https://doi.org/10.1073/pnas.95.4.1735
- Rochefort H, Glondu M, Sahla ME, et al. (2003). How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer, 10, 261-6. https://doi.org/10.1677/erc.0.0100261
- Rugo HS (2008). The breast cancer continuum in hormonereceptor- positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol, 19, 16-27. https://doi.org/10.1093/annonc/mdn300
- Sakamoto H, Yoshimura K, Saeki N, et al (2008). Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet, 40, 730-40. https://doi.org/10.1038/ng.152
- Smith LF (2007). Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol, 96, 451-2. https://doi.org/10.1002/jso.20800
- Thomas G, Jacobs KB, Kraft P, et al. (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet, 41, 579-84. https://doi.org/10.1038/ng.353
- Uray IP, Brown PH (2011). Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res, 188, 147-62.
- Wiechec E, Hansen LL (2009). The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol, 625, 122-30. https://doi.org/10.1016/j.ejphar.2009.08.045
- Williams C, Brunskill S, Altman D, et al. (2006). Costeffectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess, 10, iii-iv, ix-xi, 1-204.
- Wu X, Ye Y, Kiemeney LA, et al. (2009). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet, 41, 991-5. https://doi.org/10.1038/ng.421
- Yang X, Lippman ME (1999). BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat, 54, 1-10. https://doi.org/10.1023/A:1006189906896
- Yeager M, Xiao N, Hayes RB, et al. (2008). Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet, 124, 161-70. https://doi.org/10.1007/s00439-008-0535-3
피인용 문헌
- Characterization and function of human Ly-6/uPAR molecules vol.45, pp.11, 2012, https://doi.org/10.5483/BMBRep.2012.45.11.210
- Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2503
- Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications vol.14, pp.1, 2014, https://doi.org/10.1586/14737140.2014.845372
- Effect of Trichostatin A on CNE2 Nasopharyngeal Carcinoma Cells - Genome-wide DNA Methylation Alteration vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4663
- C13orf18 and C1orf166 (MULAN) DNA Genes Methylation are Not Associated with Cervical Cancer and Precancerous Lesions of Human Papillomavirus Genotypes in Iranian Women vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6745
- PSCA rs2294008 Polymorphism with Increased Risk of Cancer vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0136269
- PSCA rs2294008 polymorphism contributes to the decreased risk for cervical cancer in a Chinese population vol.6, pp.1, 2016, https://doi.org/10.1038/srep23465
- Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma vol.17, pp.1, 2017, https://doi.org/10.1080/14737140.2017.1266261
- The Influence of PSCA Gene Variation on Its Expression and Gastric Adenocarcinoma Susceptibility in the Northwest Chinese Population vol.16, pp.12, 2015, https://doi.org/10.3390/ijms160511648
- Impact of DCC (rs714) and PSCA (rs2294008 and rs2976392) Gene Polymorphism in Modulating Cancer Risk in Asian Population vol.7, pp.2, 2016, https://doi.org/10.3390/genes7020009